MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

Rhea-AI Summary

TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals) announced a corporate rebranding, effective July 22, 2024. The company's stock will trade under the new symbol "TNFA" on Nasdaq starting July 24, 2024. This change aligns with their focus on TNF-alpha inhibition for immuno-metabolic regulation.

Their lead candidate, MYMD-1®, is an oral TNF-alpha inhibitor targeting multiple immune-metabolic disorders. Following a successful Phase 2 study in sarcopenia completed in 2023, the company plans to advance to mid-stage clinical trials. MYMD-1 distinguishes itself from current TNF-α blockers by offering oral administration, potentially transforming treatment for autoimmune and inflammatory diseases, including age-related conditions.

Positive

• Successful completion of statistically significant Phase 2 study for MYMD-1 in sarcopenia treatment
• Advancement to mid-stage clinical trials for MYMD-1
• MYMD-1 offers oral administration, a potential advantage over current injectable TNF-α blockers
• Potential for MYMD-1 to treat multiple autoimmune and inflammatory diseases

Negative

• None.

Financial Analyst

From a financial standpoint, the rebranding of MyMD Pharmaceuticals to TNF Pharmaceuticals signals a strategic pivot towards a specific scientific focus, which can often be a bullish indicator for investors. The new brand, emphasizing TNF-alpha inhibition, is likely to attract attention from investors who are keen on niche biopharma innovations. The move to a new stock symbol 'TNFA' on Nasdaq could also garner fresh market interest and potentially impact the stock's liquidity and valuation positively. However, the long-term financial success will depend heavily on the outcomes of the upcoming clinical trials and whether MYMD-1 can secure regulatory approval and market adoption. Investors should closely monitor these key developments as they will significantly influence the company's revenue potential and stock performance.

Medical Research Analyst

The rebranding underscores the company's commitment to TNF-alpha related therapies, which is a critical area in treating autoimmune and inflammatory conditions. TNF-alpha inhibitors are a well-established class of drugs, which means TNF Pharmaceuticals is entering a competitive but potentially lucrative market. The fact that MYMD-1 is an oral TNF-alpha inhibitor sets it apart from injectable counterparts, providing a significant competitive edge. This ease of administration could lead to higher patient compliance and broader market adoption. The success of their Phase 2 study in sarcopenia, demonstrating statistically significant results, is promising. However, the upcoming mid-stage clinical trials will be crucial. Positive results could validate the drug's efficacy and safety profile, making it a strong candidate for market approval and commercialization.

Market Research Analyst

Rebranding efforts like this often aim to sharpen a company's image and market focus, which can enhance investor perception and potentially drive stock performance. The clear alignment with TNF-alpha inhibition is likely to resonate well within the biopharma sector. The transition to a new stock symbol can signal a fresh start and often results in increased market visibility. However, while these are positive steps, the actual impact on investor sentiment and stock performance will largely depend on tangible progress in their drug development pipeline. The forthcoming mid-stage clinical trials of MYMD-1 are pivotal. Should these trials build on the positive Phase 2 results, TNF Pharmaceuticals could see a strengthened market position. Conversely, any setbacks could dampen investor confidence significantly.

New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system

Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies

TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024

BALTIMORE--(BUSINESS WIRE)--

TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name “TNF Pharmaceuticals, Inc.,” effective today. The Company’s common stock, listed on the Nasdaq Capital Market, will begin trading under the new stock symbol “TNFA,” effective before the market open on Wednesday, July 24, 2024.

“Our new name, TNF Pharmaceuticals, is more closely aligned with our scientific focus on TNF-alpha, a protein in the body that plays a key role in inflammation and autoimmunity,” said the Company’s President and Chief Medical Officer Mitchell Glass, M.D. “Excess TNF-α in the blood or tissue can lead to diseases and disorders marked by acute or chronic inflammation, including age-related disorders. Our lead clinical candidate, MYMD-1®, blocks the activity of excess TNF-alpha which supports restoration of control and regulation of the immune system.”

MYMD-1 is a novel, orally dosed TNF-alpha (TNF-α) inhibitor drug for treating multiple conditions related to immune-metabolic dysregulation. A successful and statistically significant small Phase 2 study was completed in 2023, evaluating the safety and efficacy of MYMD-1 as a treatment for sarcopenia, the progressive loss of muscle mass and strength associated with aging.

“We are moving forward with mid-stage clinical trials of MYMD-1 in sarcopenia based on positive clinical data from our Phase 2 trial and previous research findings,” Dr. Glass continued. “We believe MYMD-1 could become a transformative treatment for TNF-alpha-based autoimmune and inflammatory diseases including age-related conditions.”

MYMD-1 is distinguished from currently marketed TNF-α blockers in multiple ways. It is a first-in-class oral treatment shown to reduce TNF-α and inflammation without infusion or injection. The drug’s ease of oral dosing is a strong advantage over currently available TNF-α blockers, none of which are dosed orally. Unlike systemic therapies, our oral TNF alpha inhibitor can be dose adjusted acutely and chronically for maximal safety and efficacy depending on the patient’s need.

TNF Pharmaceuticals retains the registered trademark MYMD-1® for its lead drug program. The Company’s new Investors website address is ir.tnfpharma.com.

About TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals, Inc., formerly known as MyMD Pharmaceuticals, Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1® is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company’s ability to maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and the Company’s ability to, obtain and maintain regulatory approvals for clinical trials of the Company’s pharmaceutical candidates; the timing and results of the Company’s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company’s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed by the Company on April 1, 2024, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240722253499/en/

Investor Contact:

Robert Schatz

(646) 421-9523

Source: MyMD Pharmaceuticals, Inc.

FAQ

When will TNF Pharmaceuticals (TNFA) start trading under its new stock symbol?

TNF Pharmaceuticals (TNFA) will begin trading under its new stock symbol on the Nasdaq Capital Market effective July 24, 2024.

What is the main focus of TNF Pharmaceuticals' drug development?

TNF Pharmaceuticals focuses on developing TNF-alpha inhibitors, particularly MYMD-1, to regulate the immuno-metabolic system and treat autoimmune and inflammatory conditions.

What condition did MYMD-1 show positive results for in its Phase 2 study?

MYMD-1 showed positive and statistically significant results in a Phase 2 study for sarcopenia, which is the progressive loss of muscle mass and strength associated with aging.

How does MYMD-1 differ from current TNF-α blockers on the market?

MYMD-1 is a first-in-class oral treatment, while current TNF-α blockers are administered through infusion or injection. This oral dosing offers potential advantages in terms of ease of use and dose adjustment.